05 sep: Lønstigninger er urealistiske
08 sep: Boligfesten er slut
07-09-2006 11:15:00

STRATEC raises sales and earnings forecast for 2008 to 2010

Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG today published an ad-hoc announcement

(statutory company announcement) with its sales and earnings forecast

for the 2006 and 2007 financial years. Pursuant to this announcement,

the company assumes that it will be possible to increase its sales

for 2006 to between Euro 65 million and Euro 68 million (sales

corridor) and for 2007 to between Euro 75 million and Euro 78 million

(sales corridor) and to increase its earnings before tax (EBT) to

between Euro 10.5 million and Euro 11 million in 2006 (earnings

corridor) and to between Euro 14 million and Euro 15 million in 2007

(earnings corridor).

In view of the considerable increase in the basis for the 2007

financial year, based on its current planning the company expects to

achieve an annual average growth rate (CAGR) of more than 11% in the

case of sales and of more than 16% for earnings before tax (EBT) from

2008 up to and including 2010.

As a result of the basis effect (higher basis in 2007) and the

shifting of the period under consideration by one year from 2008 the

average annual growth rate (CAGR) for our key sales and earnings

figures is lower in percentage terms, yet higher in absolute terms,

in the long-term forecast (for 2008 to 2010) than in the forecast

published in December 2005 (for 2007 to 2009). Assuming that the

targets stated in our long-term forecast are met, the average annual

growth rate (CAGR) reported by the STRATEC Group for the financial

years from 2000 to 2010 would amount to more than 25% in the case of

sales and to more than 34% in the case of earnings before tax (EBT).

The forecast for 2008 to 2010 takes only limited account of the

conclusion of outstanding new development and supply agreements for

new analyzer system families with existing and new customers.

The new budget figures are considerably higher than the internal

budget targets most recently forecast in December 2005. These

forecast that the sales for the 2006 financial year would increase to

Euro 55 million to Euro 59 million (sales corridor) and that earnings

before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million

(earnings corridor). An average annual growth rate (CAGR) of more

than 15% in the case of sales and of more than 22% for earnings

before tax (EBT) was forecast for the subsequent 2007 to 2009

financial years.

The annual average growth (CAGR) reported for the financial years

from 2000 up to and including 2005 amounted to more than 32% in terms

of sales and to more than 40% in the case of earnings before tax

(EBT).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 apr
OMXC25
Som tidligere påvist kan bulls køre hen over hvilken som helt bear. Hvis de altså vil. Det kræver at..
30
19 apr
 
Et opgør med Finanstilsynet er tvingende nødvendigt, hvis tilliden til markedet ikke skal lægges øde..
28
18 apr
 
LÆS NU FOR HELVEDE NOGEN AF DE 38000 indlæg som siger at børsen er nede!   Det er kraftstejleme da u..
21
20 apr
VWS
Vestas har en ordrerbeholdning større end de nogensinde har haft, og de sendte en næsten færdigjort ..
20
19 apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
20 apr
VWS
hvornår kommer analysen?
16
18 apr
 
Det er en katastrofe ! Hvis det fortsætter ret meget længere er vi allesammen nødt til at gå ud og l..
16
17 apr
LAUR
An aktie man aldrig skal eje. Ejerne trækker store summer ud, at en virksomhed der kæmper for overle..
14
21 apr
VELO
Jeg har i torsdags købt Veloxis igen efter en længere pause. For efterhånden en del år siden stod de..
13
19 apr
 
Hej alle,   Jeg lavede et lille indlæg på Stolt-Nielsen for nylig hvor jeg desværre – og det beklage..
13

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Vestas-konkurrent sælger flere vindmøller - men prispresset fortsætter

20-04-2018 12:49:56
Den amerikanske Vestas-konkurrent General Electric (GE) har solgt flere vindmøller i første kvartal, men selskabet melder om fortsat prispres i branchen. GE havde i de første tre måneder af 2018 en ordreindgang på 936 vindmøller mod 589 i samme periode sidste år. Selskabet oplyser ikke størrelsen på de solgte møller, men skriver i en kommentar, at det har haft en stærk vækst i USA målt på megawatt..

Brøndby-aktien banker til vejrs efter sejr over guldrival

20-04-2018 09:20:41
Aktien i Brøndby IF bliver sendt til vejrs med en stigning på 13,6 pct. til 1,25 kr. fredag morgen, efter at fodboldklubben torsdag aften vandt 3-2 på udebane over FC Midtjylland i Alka Superligaen.Med sejren fastholder Brøndby IF sin førsteplads i Alka Superligaen og har nu tre point ned til netop FC Midtjylland på andenpladsen. Der mangler at blive spillet seks runder, før sæsonen er slut i Alka..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. april 2018 23:43:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180417.1 - EUROWEB6 - 2018-04-22 23:43:58 - 2018-04-22 23:43:58 - 1 - Website: OKAY